Drug Database
YY

YY-3110 (YY 3110 / YY3110)

✓ Approved

YuYu Pharma · Small Molecule · Small Molecule

What is YY-3110?

YY-3110 is a small molecule developed by YuYu Pharma. It is approved for therapeutic indications via unknown.

Drug Profile

Brand NamesYY 3110, YY3110
CompanyYuYu Pharma
Drug ClassSmall Molecule
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, YuYu Pharma

Therapeutic Indications

YY-3110 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Vascular disordersThrombosis✓ Approved

Related Research Articles

PubMedInternational journal of biological macromolecules2026-09-15

Effects of nonionic surfactants on the production of extracellular polysaccharides, citrinin synthesis, physicochemical structural characteristics, and in vitro hypoglycaemic activity of Monascus purpureus YY-1.

Wang Xiaohui X, Wang Lu L, Ma Qihao Q, Dai Shihao S et al.

Monascus extracellular polysaccharides exhibit diverse bioactivities, including antioxidant, antitumor, and immunomodulatory effects. Nevertheless, their low native yield restricts practical applications. To improve the fermentation yield and functional properties of EPS, Monascus purpureus YY-1 was employed as the experimental strain in this study. We systematically investigated the regulatory effects of three nonionic surfactants (Triton X-100, Brij 35, and Span 60) on EPS production, citrinin accumulation, physicochemical structures of polysaccharides, and their in vitro hypoglycemic activity of the strain. The results demonstrated that nonionic surfactants significantly elevated EPS yields by enhancing fungal cell membrane permeability, achieving an overall increase of 10%-20% relative to the blank control group. Meanwhile, these surfactants effectively inhibited the biosynthesis and accumulation of citrinin during fermentation, improving product safety. Among these, the polysaccharides (T-EPS) obtained with Triton X-100 exhibit higher total sugar content, a more favorable galactose-to-mannose ratio, lower average molecular weight and particle size, and display a typical triple-helix conformation and a loose, porous micro-morphology. These favorable physicochemical structural features confer T-EPS with stronger inhibitory activities against α-amylase and α-glucosidase, as well as superior glucose adsorption capacity. This study confirms that nonionic surfactants (especially Triton X-100 with optimal performance) can synergistically enhance the yield, safety, and hypoglycemic activity of Monascus EPS. It provides important theoretical support for the development and application of functional polysaccharides from Monascus in the field of hypoglycemic functional foods.

PMID 42735587
Read full article →
PubMedOncogene2026-09-13

Development and preclinical evaluation of a decoy DLL4-encoding oncolytic HSV-1 for high-grade glioma.

Rivera-Caraballo Kimberly A KA, Vázquez-Arreguín Karina K, Singh Harmanpreet H, Sahu Upasana U et al.

Preclinical and clinical investigation of oncolytic HSV-1 (oHSV) treatment for cancer has indicated increased Notch signaling in tumors after treatment. Since Notch activation often heralds cancer cell stemness, angiogenesis, and invasion, the induction of this pathway after oHSV virotherapy can support tumor growth and limit response to virotherapy. Here, we evaluated the impact of blocking DLL4, a Notch ligand, on virotherapy. Matched tumor biopsies pre- and post-oHSV (CAN-3110, NCT03152318) treatment revealed an induction of DLL4 post-therapy. We observed that expression of a recombinant soluble decoy DLL4 (sDLL4) could block Notch activation in tumor cells. Thus, we engineered an oHSV vector designed to encode soluble DLL4 (OVsDLL4) to block ligand-mediated Notch signaling. RNA sequencing and gene set enrichment analysis revealed that, relative to control oHSV, OVsDLL4 blocked Notch and sprouting angiogenesis pathways after treatment. Despite slower virus replication in vitro, OVsDLL4 cytotoxicity remained effective against tumor cells. Transcriptome profiling also indicated a significant dysregulation of metabolic pathways related to oxidative phosphorylation and glutathione metabolism, in accordance with increased oxygen consumption observed by Seahorse analysis in cells expressing sDLL4. OVsDLL4-treated cells further showed increased reactive oxygen species relative to control oHSV-treated cells. Co-culture of infected tumor cells with immune cells revealed that OVsDLL4 treatment polarized them toward an inflammatory phenotype. In vivo, the therapeutic efficacy of OVsDLL4 was underscored, as treatment of glioma-bearing mice resulted in reduced tumor burden and prolonged survival.

PMID 42732006
Read full article →
PubMedJournal of applied microbiology2026-09-13

Safety and Efficacy of Lacticaseibacillus rhamnosus LRa05, Limosilactobacillus reuteri LR08 and Lactobacillus crispatus LCr86 on Hormone Metabolism, Body Composition, and Emotional Regulation in Overweight Women: A Randomized, Double - Blind, Placebo - Controlled Trial.

Yin Lingxin L, Wang Shanni S, Liu Yinhua Y, Zhu Chengsheng C et al.

Female obesity is linked to dysfunction of the endocrine-metabolic-gut-brain axis. Probiotics may offer therapeutic benefits, but robust evidence is limited. To investigate the effects of a 12-week multi-strain probiotic intervention on endocrine, metabolic, psychological parameters, and gut microbiota in obese women. In a randomized, double-blind, placebo-controlled trial, 102 obese women received daily probiotics (Lacticaseibacillus rhamnosus LRa05, Limosilactobacillus reuteri LR08 and Lactobacillus crispatus LCr86) or placebo for 12 weeks. Hormones, anthropometric measures, psychological scores, and gut microbiota were assessed at baseline and endpoint. Probiotics selectively modulated the endocrine-metabolic axis. Compared to placebo, prolactin, adrenocorticotropic hormone, and leptin decreased, while glucagon-like peptide-1 and peptide YY increased (p < 0.05). Body weight, BMI, waist and hip circumference, and body fat percentage declined significantly (p < 0.05). Anxiety and depression scores improved markedly (p < 0.001). Gut microbiota showed increased Faecalibacterium and decreased Collinsella abundance (p < 0.05). A 12-week multi-strain probiotic intervention was associated with improvements in body composition and emotional status, as well as favorable changes in appetite- and stress-related hormonal profiles and gut microbial composition in women with obesity. Clinical Trial Registration: NCT07013409 (ClinicalTrials.gov).

PMID 42731127
Read full article →
PubMedHormones and behavior2026-09-11

Circulating peptide YY shows no postprandial response and is unrelated to feeding behavior in zebra finches.

Davies Scott S, Lamparillo Michael M, Hartman Alexa A, Boko Defamien D et al.

The regulation of feeding behavior, particularly the timely cessation of food intake, is essential for maintaining energy balance. In mammals, the gut-derived hormone peptide YY (PYY) plays an important role in short-term satiety signaling, with circulating concentrations increasing rapidly after meals to suppress further food intake. In non-mammalian vertebrates, however, the role of PYY in satiety signaling remains poorly understood. The aim of the present study was to test the hypothesis that circulating PYY functions as a short-term satiety signal in birds, analogous to its established role in mammals. We compared preprandial and postprandial circulating PYY concentrations in adult zebra finches (Taeniopygia guttata) that were either food-restricted for 20 days or fed ad libitum. In addition, we quantified feeding motivation, measured as latency to initiate feeding, and food consumption to assess whether variation in circulating PYY was associated with feeding behavior. Contrary to our predictions, circulating PYY concentrations did not increase following feeding, did not significantly differ between food-restricted and ad libitum birds, and were unrelated to either feeding latency or food consumption. Collectively, these findings fail to support the hypothesis that PYY functions as a conserved short-term satiety signal in zebra finches. Instead, our results suggest that the role of PYY in zebra finches may differ from the mammalian pattern and highlight the need for additional comparative studies in birds.

PMID 42727548
Read full article →
PubMedNanomaterials (Basel, Switzerland)2026-09-11

Optimization of Cytokinesis-Block Micronucleus Assay for Clastogenic Risk Assessment of Silver-Containing Nanomaterials.

Yang Ying Y, Shao Zixuan Z, Li Qiu Q, Jiang Chenchen C et al.

Nanomaterials have been extensively incorporated and are commonly used in everyday life. Rising human exposure to risks has highlighted the carcinogenic hazards from prolonged exposure, prompting the development of "Nanogenotoxicology" as a distinct academic field. However, conventional in vitro micronucleus assay systems cannot ensure adequate contact between nanomaterials and cellular genetic material, which prevents an accurate assessment of the clastogenic risk posed by nanomaterials. In this study, the p53-competent human cell line TK6 and the karyotypically stable conventional cell line CHL were used to conduct a cytokinesis-block micronucleus assay (CBMN), and the cytoskeleton inhibitor cytochalasin B was added to the culture system after nanomaterial exposure. Ag40 (40 nm silver nanoparticles) and polystyrene microspheres were employed as the nanoscale positive and negative controls, respectively. Prior to this study, hyperspectral imaging and inductively coupled plasma mass spectrometry were used to verify that the cellular association of Ag40 was not markedly affected by the addition of rat liver S9 mixture and cytochalasin B. Our results showed that, under exposure periods of 4 h (with or without rat liver S9 mixture), 24 h, 48 h and 72 h, Ag40 at concentrations ranging from 5 to 40 µg/mL significantly increased the micronucleus frequency up to 6%, while polystyrene microspheres showed negative results. Therefore, Ag40 and polystyrene microspheres were identified as the respective nanoscale positive and negative controls for CBMN. The established method was further validated in two independent laboratories using a nano-silver burn wound dressing, and both chemical and nanoscale controls were included. The methodology developed in the present study provided a foundational basis for the development of the standard YY/T 1897-2023 in China.

PMID 42726539
Read full article →
PubMedClinical science (London, England : 1979)2026-09-10

How lipid ingestion is sensed: the mechanisms underlying intestinal hormone secretion.

Santos-Hernández Marta M, Gribble Fiona M FM, Reimann Frank F

Dietary lipids are potent stimulators of intestinal hormone secretion, which plays a central role in the regulation of digestion, appetite, glucose homeostasis, and lipid metabolism. Following digestion in the intestinal lumen, lipid-derived molecules are detected through complementary mechanisms involving lipid transporters, nutrient-sensing receptors, intracellular metabolic pathways, and bile acid signaling. These pathways couple nutrient availability to the secretion of enteroendocrine hormones, including glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), peptide YY (PYY), cholecystokinin (CCK), ghrelin and serotonin, thereby coordinating local and systemic metabolic responses. In the small intestine, CD36 contributes to lipid uptake and sensing, while intracellular lipid processing and chylomicron formation influence hormone secretion. Bile acids facilitate lipid digestion and absorption and further regulate enteroendocrine function through receptor-mediated signaling pathways. This review examines the cellular and molecular mechanisms underlying intestinal lipid sensing, with particular emphasis on the roles of CD36, chylomicron formation, bile acid signaling, and nutrient-sensing receptors in the regulation of enteroendocrine hormone secretion.

PMID 42719962
Read full article →

+4526 more articles available with a free account

Sign up free to view all articles →

Ask about YY-3110